The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
An estimated 21 million American women experience BV
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Air purification system achieves Intertek zero ozone certification
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Subscribe To Our Newsletter & Stay Updated
